John Billimek Selected Research

John Billimek Research Topics

5	Type 2 Diabetes Mellitus (MODY) 01/2020 - 12/2009
2	Neoplasms (Cancer) 11/2022 - 01/2020
2	Prostatic Neoplasms (Prostate Cancer) 03/2018 - 07/2013
1	Colorectal Neoplasms (Colorectal Cancer) 11/2022
1	Wounds and Injuries (Trauma) 12/2021
1	Stab Wounds (Stab Wound) 12/2021
1	Meningioma (Meningiomas) 01/2020
1	Spinal Dysraphism (Spina Bifida) 12/2017
1	Ischemia 09/2017
1	Reperfusion Injury 09/2017
1	Myocardial Ischemia (Ischemic Heart Diseases) 09/2017
1	Atrophy 01/2016
1	Dyslipidemias (Dyslipidemia) 01/2015
1	Prader-Willi Syndrome (Syndrome, Prader-Willi) 05/2014
1	Pain (Aches) 01/2014

3	Glucose (Dextrose)FDA LinkGeneric 01/2014 - 12/2009
1	Immune Checkpoint InhibitorsIBA 11/2022
1	Explosive Agents (Explosives)IBA 12/2021
1	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2020
1	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2020
1	Progesterone FDA LinkGeneric 01/2020
1	thiamine triphosphorate (TTP)IBA 01/2020
1	Octreotide (Sandostatin)FDA LinkGeneric 01/2020
1	Pharmaceutical PreparationsIBA 01/2020
1	Estrogens (Estrogen)FDA Link 01/2020
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2020
1	Cholinergic Antagonists (Anticholinergics)IBA 12/2017
1	Proteins (Proteins, Gene)FDA Link 09/2017
1	Single-Chain AntibodiesIBA 09/2017
1	Monoclonal AntibodiesIBA 09/2017
1	Temozolomide (Temodar)FDA LinkGeneric 01/2016
1	Bevacizumab (Avastin)FDA Link 01/2016
1	LipidsIBA 01/2015
1	Growth Hormone (Somatotropin)IBA 05/2014

4	Therapeutics 11/2022 - 12/2009
2	Drug Therapy (Chemotherapy) 11/2022 - 01/2020
2	Glycemic Control 01/2020 - 12/2009
1	Biological Therapy 11/2022
1	Castration 03/2018
1	Aftercare (After-Treatment) 01/2015
1	Complementary Therapies (Alternative Medicine) 11/2014